Photo by nci from unsplash
8013Background: The proteasome inhibitor (PI) ixazomib (Ixz) is the first orally administered PI approved for treating multiple myeloma (MM). It has shown clinical activity as a single agent and wh... Click to show full abstract
8013Background: The proteasome inhibitor (PI) ixazomib (Ixz) is the first orally administered PI approved for treating multiple myeloma (MM). It has shown clinical activity as a single agent and wh...
Keywords:
relapsed refractory;
ixazomib;
multiple myeloma;
ixazomib relapsed;
replacement ixazomib
Journal Title: Journal of Clinical Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!